Mezzion Pharma Co., Ltd. Logo

Mezzion Pharma Co., Ltd.

Develops and out-licenses novel therapeutics like udenafil, with a focus on rare diseases.

140410 | KO

Overview

Corporate Details

ISIN(s):
KR7140410002
LEI:
Country:
South Korea
Address:
서울특별시 강남구 삼성로 570 석천빌딩 7층, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mezzion Pharma Co., Ltd. is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics, with a particular emphasis on rare diseases. The company's primary efforts are centered on its drug candidate, udenafil, for various medical conditions. A key initiative is the development of udenafil for adolescents living with Fontan circulation, a rare congenital heart condition, supported by a large-scale Phase 3 clinical trial (FUEL-2). Mezzion's pipeline also includes potential treatments for pulmonary arterial hypertension (PAH), portal hypertension, and erectile dysfunction. The company's business model involves developing pharmaceutical products and out-licensing them for international markets.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-17 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 14.7 KB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.1 MB
2025-08-08 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 27.9 KB
2025-06-20 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 6.0 KB
2025-06-20 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 6.0 KB
2025-06-13 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 101.3 KB
2025-06-13 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 107.8 KB
2025-06-10 00:00
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
Korean 67.0 KB
2025-06-10 00:00
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
Korean 94.9 KB
2025-06-05 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 27.1 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 972.3 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 24.7 KB
2025-03-20 00:00
Annual Report
사업보고서 (2024.12)
Korean 1.5 MB
2025-03-14 00:00
Audit Report / Information
감사보고서제출
Korean 25.8 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 143.7 KB

Automate Your Workflow. Get a real-time feed of all Mezzion Pharma Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Mezzion Pharma Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Mezzion Pharma Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Clinical-stage biopharma developing novel cancer drugs aiming for fewer side effects.
Japan
4575
Candel Therapeutics, Inc. Logo
Developing off-the-shelf viral immunotherapies to help the immune system fight solid tumors.
United States of America
CADL
Can-Fite BioPharma Ltd. Logo
Develops oral small-molecule drugs targeting A3AR for oncology and inflammatory diseases.
Israel
CANF
Cannovum Cannabis AG Logo
Importer & producer of medical cannabis, expanding into recreational cultivation infrastructure.
Germany
27N0
Canopy Growth Corp Logo
Produces diverse cannabis products for medical and recreational markets globally.
United States of America
CGC
Cantourage Group SE Logo
A European platform producing and distributing medical cannabis products to pharmacies.
Germany
HIGH
CAPRICOR THERAPEUTICS, INC. Logo
Develops cell and exosome-based therapeutics for rare diseases like Duchenne muscular dystrophy.
United States of America
CAPR
CAREGEN CO.,LTD. Logo
Develops patented peptides and growth factors for medical aesthetics, pharma, and anti-aging markets.
South Korea
214370
Caribou Biosciences, Inc. Logo
Uses CRISPR genome editing to create off-the-shelf CAR-T cell therapies for cancer.
United States of America
CRBU
Carisma Therapeutics Inc. Logo
Developing engineered macrophage (CAR-M) therapies for solid tumors and autoimmune diseases.
United States of America
CARM

Talk to a Data Expert

Have a question? We'll get back to you promptly.